Semaglutide, tirzepatide and retatrutide are often displayed in a single weight-loss ranking. That presentation can conceal differences in product approval, receptor targets, patient populations and trial design. A useful comparison identifies those differences before displaying outcomes.

SURMOUNT-5 directly compared tirzepatide with semaglutide in adults with obesity without diabetes. SURMOUNT-5: tirzepatide compared with semaglutide It provides a stronger basis for that particular comparison than matching numbers from unrelated studies. Its conclusions still apply to the tested products, population and follow-up rather than every possible use.

Retatrutide's TRIUMPH-1 publication adds phase 3 evidence, but it is a separate placebo-controlled study. TRIUMPH-1: Retatrutide for treatment of obesity Its results should not be treated as a head-to-head finding against either of the other agents. A larger percentage from another trial can reflect differences in duration, eligibility or analysis as well as pharmacology.

Regulatory status remains separate from the efficacy chart. Approved semaglutide and tirzepatide formulations have product-specific indications, while FDA's reviewed communication identifies retatrutide as unapproved. FDA: Concerns with unapproved GLP-1 drugs That distinction should be visible wherever the three are discussed together.

Readers should examine safety, discontinuations and the meaning of the reported estimate. Did the analysis include outcomes after stopping treatment, or model what might happen if treatment continued? Were people with diabetes included? Were the goals weight change alone or other clinical outcomes? These details can change the practical interpretation.

This article does not choose a medicine or a research candidate for an individual. It offers a comparison framework: prioritize direct evidence when available, label indirect comparisons and avoid translating investigational results into product availability or self-use recommendations. Clinical decisions require current labeling and a clinician's assessment of the person's circumstances.